MCID: NRF003
MIFTS: 43

Neurofibrosarcoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neurofibrosarcoma

MalaCards integrated aliases for Neurofibrosarcoma:

Name: Neurofibrosarcoma 12 76 53 29 13 55 6 44 15 73
Malignant Peripheral Nerve Sheath Tumor 73
Neurosarcoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3512
MeSH 44 D018319
SNOMED-CT 68 19897006

Summaries for Neurofibrosarcoma

MalaCards based summary : Neurofibrosarcoma, also known as malignant peripheral nerve sheath tumor, is related to malignant peripheral nerve sheath tumor and neurofibroma. An important gene associated with Neurofibrosarcoma is MXI1 (MAX Interactor 1, Dimerization Protein), and among its related pathways/superpathways is Glioblastoma Multiforme. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 A malignant peripheral nerve sheath tumor (MPNST) (also known as "malignant schwannoma",... more...

Related Diseases for Neurofibrosarcoma

Diseases related to Neurofibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 malignant peripheral nerve sheath tumor 33.0 NF1 NF2
2 neurofibroma 30.4 NF1 NF2
3 plexiform neurofibroma 30.0 NF1 NF2
4 childhood malignant schwannoma 11.1
5 adult malignant schwannoma 11.1
6 neurofibromatosis, type i 10.2
7 sarcoma 10.2
8 tièche-jadassohn nevus 10.1
9 neurofibromatosis, familial spinal 10.1 NF1 NF2
10 plexiform schwannoma 10.1 NF1 NF2
11 immature cataract 10.1 NF1 NF2
12 atypical neurofibroma 10.1 NF1 NF2
13 trigeminal nerve neoplasm 10.1 NF1 NF2
14 neurilemmoma 10.1 NF1 NF2
15 neurilemmoma of the fifth cranial nerve 10.1 NF1 NF2
16 amyloid tumor 10.1 NF1 NF2
17 spinal meningioma 10.1 NF1 NF2
18 spinal canal and spinal cord meningioma 10.1 NF1 NF2
19 neurilemmomatosis 10.1 NF1 NF2
20 optic nerve neoplasm 10.1 NF1 NF2
21 acoustic neuroma 10.1 NF1 NF2
22 nervous system benign neoplasm 10.1 NF1 NF2
23 cellular schwannoma 10.1 NF1 NF2
24 neurofibromatosis, type ii 10.1 NF1 NF2
25 elephantiasis 10.0 INSRR NF1
26 hypoglycemia 10.0
27 peripheral nervous system neoplasm 10.0 NF1 NF2
28 neurofibromatosis, type iv, of riccardi 10.0 NF1 NF2
29 central nervous system cancer 10.0 NF1 NF2
30 nervous system cancer 10.0 NF1 NF2
31 autosomal genetic disease 9.9 NF1 NF2
32 ependymoma 9.9 NF2 TP73
33 spondyloarthropathy 1 9.9
34 ovarian cancer 9.9
35 pheochromocytoma 9.9
36 lymphoma, hodgkin, classic 9.9
37 myasthenia gravis 9.9
38 wilms tumor 6 9.9
39 angiosarcoma 9.9
40 lymphoma 9.9
41 graves' disease 9.9
42 hyperinsulinemic hypoglycemia 9.9
43 leiomyosarcoma 9.9
44 neuroma 9.9
45 thymoma 9.9
46 femoral neuropathy 9.9
47 spondylitis 9.9
48 neuropathy 9.9
49 myasthenia gravis congenital 9.9
50 opsoclonus-myoclonus syndrome 9.9

Graphical network of the top 20 diseases related to Neurofibrosarcoma:



Diseases related to Neurofibrosarcoma

Symptoms & Phenotypes for Neurofibrosarcoma

GenomeRNAi Phenotypes related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 9.44 DCK
2 Decreased viability GR00221-A-1 9.44 DCK INSRR NF1
3 Decreased viability GR00221-A-2 9.44 DCK NF1
4 Decreased viability GR00221-A-4 9.44 DCK NF1
5 Decreased viability GR00240-S-1 9.44 DCK
6 Decreased viability GR00301-A 9.44 INSRR
7 Decreased viability GR00402-S-2 9.44 DCK INSRR NF1

MGI Mouse Phenotypes related to Neurofibrosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.55 DCK MXI1 NF1 NF2 TP73
2 neoplasm MP:0002006 9.26 MXI1 NF1 NF2 TP73
3 renal/urinary system MP:0005367 8.92 INSRR MXI1 NF1 NF2

Drugs & Therapeutics for Neurofibrosarcoma

Drugs for Neurofibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
8
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
10
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
11
Epirubicin Approved Phase 3 56420-45-2 41867
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
14
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
15
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
16
Cyproheptadine Approved Phase 3 129-03-3 2913
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
18
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
22 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
24 Immunologic Factors Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Etoposide phosphate Phase 3,Phase 2
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
29 Antimitotic Agents Phase 3,Phase 2,Phase 1
30 Antirheumatic Agents Phase 3,Phase 1
31 Nucleic Acid Synthesis Inhibitors Phase 3
32 Imatinib Mesylate Phase 2, Phase 3,Phase 1 220127-57-1 123596
33 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Antimetabolites Phase 3,Phase 2,Phase 1
36 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
37 Serotonin Agents Phase 3
38 Anti-Allergic Agents Phase 3
39 Serotonin Antagonists Phase 3
40 Histamine H1 Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Antipruritics Phase 3
43 Neurotransmitter Agents Phase 3
44 Dermatologic Agents Phase 3
45 Histamine Antagonists Phase 3
46 Gastrointestinal Agents Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
49
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
6 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
7 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
11 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
12 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
13 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Unknown status NCT01661283 Phase 2 everolimus;bevacizumab
17 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
18 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
19 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
20 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
21 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
22 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
23 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
27 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
28 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
29 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
30 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
31 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
32 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
34 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
35 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
36 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
37 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
38 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
39 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 Completed NCT02096471 Phase 2 PD-0325901
40 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
41 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
42 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
43 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
44 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
45 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
46 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
47 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
48 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
49 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
50 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib

Search NIH Clinical Center for Neurofibrosarcoma

Cochrane evidence based reviews: neurofibrosarcoma

Genetic Tests for Neurofibrosarcoma

Genetic tests related to Neurofibrosarcoma:

# Genetic test Affiliating Genes
1 Neurofibrosarcoma 29

Anatomical Context for Neurofibrosarcoma

MalaCards organs/tissues related to Neurofibrosarcoma:

41
Bone, Lung, Breast, Kidney, Prostate, Testis, Brain

Publications for Neurofibrosarcoma

Articles related to Neurofibrosarcoma:

(show top 50) (show all 689)
# Title Authors Year
1
Malignant peripheral nerve sheath tumor of the trigeminal nerve involving the middle and posterior cranial fossa. ( 29408426 )
2018
2
Malignant peripheral nerve sheath tumor: The need to get it right first time around. ( 29115724 )
2018
3
Malignant peripheral nerve sheath tumor of the scalp: Two rare case reports. ( 29900032 )
2018
4
Case Report: Metastasis of a Trigeminal Malignant Peripheral Nerve Sheath Tumor to the Corpus Callosum. ( 29518229 )
2018
5
Atypical presentation of a primary cardiac malignant peripheral nerve sheath tumor. ( 29318408 )
2018
6
Targeted next-generation sequencing of malignant peripheral nerve sheath tumor of the pterygopalatine fossa with intracranial metastatic recurrence. ( 29369179 )
2018
7
Case of an Intracranial Malignant Peripheral Nerve Sheath Tumor in the Setting of Pacer-dependent Heart Block. ( 29492148 )
2018
8
Immunohistochemical analysis of epigenetic factors to differentiate malignant peripheral nerve sheath tumor from benign neurofibroma in a patient with mosaic neurofibromatosis type 1: H3 lysine 27 trimethylation stain and enhancer of zeste homolog 2 stain. ( 29687471 )
2018
9
Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status. ( 29309298 )
2018
10
Extensive perineural spread of an intrapelvic sciatic malignant peripheral nerve sheath tumor: a case report. ( 29974241 )
2018
11
Low- Grade Malignant Peripheral Nerve Sheath Tumor Mimicking a Schwannoma: The Role and Importance of Trimethylated H3K27M Staining. ( 29909207 )
2018
12
Malignant Peripheral Nerve Sheath Tumor in a Patient With BAP1 Tumor Predisposition Syndrome. ( 29061454 )
2018
13
Retrobulbar malignant peripheral nerve sheath tumor in a golden retriever dog: A challenging diagnosis. ( 29606723 )
2018
14
CASE SERIES: Malignant Peripheral Nerve Sheath Tumor in the Course of the Mandibular Nerve. ( 29883816 )
2018
15
A case report of cervical neurofibrosarcoma: Clinical presentation, treatment and outcome. ( 29253810 )
2018
16
Supraclavicular Brachial Plexus Neurolysis for a Malignant Peripheral Nerve Sheath Tumor: A Case Report. ( 29894352 )
2018
17
Correction: Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 29543881 )
2018
18
Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. ( 29332262 )
2018
19
Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2. ( 30408304 )
2018
20
Linear Accelerator Based Stereotactic Radiosurgery for Cranial, Intraparenchymal Metastasis of a Malignant Peripheral Nerve Sheath Tumor: Case Report and Review of the Literature. ( 30529515 )
2018
21
Malignant Peripheral Nerve Sheath Tumor of the Parotid Gland. ( 30538405 )
2018
22
Melanoma Mimicking Malignant Peripheral Nerve Sheath Tumor with Spread to the Cerebellopontine Angle: Utility of Next-Generation Sequencing in Diagnosis. ( 30050716 )
2018
23
Targeting of AKT/ERK/CTNNB1 by DAW22 as a potential therapeutic compound for malignant peripheral nerve sheath tumor. ( 30112810 )
2018
24
Cutaneous metastases of malignant peripheral nerve sheath tumor: Ineffectiveness of intralesional methotrexate. ( 30128346 )
2018
25
Malignant Peripheral Nerve Sheath Tumor Arising in Schwannomatosis with Multiple Lung Metastases. ( 30144611 )
2018
26
Malignant peripheral nerve sheath tumor originating from the adrenal gland in a dog. ( 30175755 )
2018
27
Malignant peripheral nerve sheath tumor of the thorax: Unusual location of a rare tumor. ( 30197366 )
2018
28
Malignant peripheral nerve sheath tumor of the breast in a patient with neurofibromatosis 1. ( 30230131 )
2018
29
Primary malignant peripheral nerve sheath tumor of prostate in a young adult: A case report. ( 30278486 )
2018
30
Spontaneous Transformation of Vestibular Schwannoma into Malignant Peripheral Nerve Sheath Tumor. ( 30283553 )
2018
31
BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. ( 30310175 )
2018
32
A recurrent laryngeal nerve malignant peripheral nerve sheath tumor in a child with neurofibromatosis type 1. ( 30365627 )
2018
33
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. ( 28752843 )
2017
34
Fluorine-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography Masquerading as a Case of Sporadic Malignant Peripheral Nerve Sheath Tumor of Lower Extremity Presenting as Massive Lower Limb Edema. ( 29033684 )
2017
35
Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor. ( 27706810 )
2017
36
Malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1. ( 28658406 )
2017
37
Radiation-Induced Glandular Malignant Peripheral Nerve Sheath Tumor. ( 28530162 )
2017
38
The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells. ( 28502478 )
2017
39
Rexin-G(Ar), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. ( 28588778 )
2017
40
Malignant Peripheral Nerve Sheath Tumor of the Femur: A Rare Diagnosis Supported by Complete Immunohistochemical Loss of H3K27me3. ( 28508686 )
2017
41
Malignant Peripheral Nerve Sheath Tumor of the Inguinum and Angiosarcoma of the Scalp in a Child with Neurofibromatosis Type 1. ( 29138703 )
2017
42
Metastatic Epithelioid Malignant Peripheral Nerve Sheath Tumor in a Known Case of Neurofibromatosis-1, Cytomorphological Appearance, and Critical Analysis of Immunohistochemistry. ( 29200699 )
2017
43
Metastatic angiosarcoma arising in malignant peripheral nerve sheath tumor in a young patient with neurofibromatosis type 1. ( 28548697 )
2017
44
Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens. ( 28898989 )
2017
45
CHD4 as a Potential Biomarker in Differentiating Between Cellular Schwannoma and Malignant Peripheral Nerve Sheath Tumor. ( 28549031 )
2017
46
Primary Intraosseous Malignant Peripheral Nerve Sheath Tumor of Metacarpal Bones of the Hand in a Patient Without Neurofibromatosis 1: Report of a Rare Case. ( 28900340 )
2017
47
Spindle cell type malignant peripheral nerve sheath tumor arising in benign schwannoma with multiple intraosseous spinal metastasis: A case report. ( 28505957 )
2017
48
Hemisacrectomy with preservation of the contralateral sacral nerve roots and sacroiliac joint for pelvic neurofibrosarcoma in a 7-year-old child: case report with 2-year follow-up. ( 27689246 )
2017
49
Malignant peripheral nerve sheath tumor in children: A single-institute retrospective analysis. ( 29286874 )
2017
50
Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 28558056 )
2017

Variations for Neurofibrosarcoma

ClinVar genetic disease variations for Neurofibrosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MXI1 NM_130439.3(MXI1): c.362C> T (p.Ala121Val) single nucleotide variant Pathogenic rs137852604 GRCh37 Chromosome 10, 111988034: 111988034
2 MXI1 NM_130439.3(MXI1): c.362C> T (p.Ala121Val) single nucleotide variant Pathogenic rs137852604 GRCh38 Chromosome 10, 110228276: 110228276

Expression for Neurofibrosarcoma

Search GEO for disease gene expression data for Neurofibrosarcoma.

Pathways for Neurofibrosarcoma

Pathways related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.67 NF1 NF2

GO Terms for Neurofibrosarcoma

Biological processes related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.33 MXI1 NF1 NF2
2 negative regulation of protein kinase activity GO:0006469 9.26 NF1 NF2
3 negative regulation of MAPK cascade GO:0043409 8.96 NF1 NF2
4 negative regulation of cell-matrix adhesion GO:0001953 8.62 NF1 NF2

Sources for Neurofibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....